A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether there is a survival benefit with lintuzumab
given in combination with low dose cytarabine versus low dose cytarabine and placebo in
patients with AML.